Jun 25, 2021
Sibylla Biotech selected by Nature among the eight best start-ups in the world in the life-science sector Sibylla Biotech, a spin-off of INFN, the University of Trento, and the University of Perugia, has been selected, the only Italian company, as a finalist of the...
May 22, 2021
Sibylla Biotech will use its Drug Discovery platform to modulate the activity of targets supplied by Takeda. The Italian startup company will partner its innovative PPI-FIT Drug Discovery platform with Takeda to generate novel compounds designed to modulate the...
Jan 22, 2021
The scientific paper about PPI-FIT technology and its first validation is now published on Nature Communications Biology! Spagnolli, G., Massignan, T., Astolfi, A. et l. Pharmacological inactivation of the prion protein by targeting a folding intermediate. Commun...
Apr 22, 2020
New structural target against COVID-19 A new structural target for drug development against COVID-19 has been unveiled today by Sibylla Biotech in collaboration with the Italian National Institute of Nuclear Physics (INFN), the University of Trento and University of...
Jan 23, 2020
A documentary on Sibylla Biotech broadcasted on TV 4.0 La fabbrica del futuro
